AbbVie Launches PRODUODOPA® in the EU for Advanced Parkinson’s Disease
AbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreAbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreAlzheimer’s disease (AD) and Parkinson’s disease (PD) stand as the two most prevalent neurodegenerative disorders, each characterized by the cerebral
Read moreStressMarq Biosciences, a pioneer in the development and commercialization of unique fibrilized and oligomeric protein preparations to propel the study
Read moreA collaboration between StressMarq Biosciences and Gubra has generated a 3D whole-brain light sheet fluorescence imaging model depicting alpha-synuclein pSer129+
Read moreStressMarq manufactures and offers a wide range of products specifically developed to accelerate Parkinson’s disease research. StressMarq’s cutting-edge product range
Read moreStressMarq has developed unique Superoxide Dismutase 1 (SOD1) Pre-formed Fibrils (PFFs) and monomers for neurodegenerative disease research, particularly valuable for
Read moreStressMarq has developed unique Transthyretin (TTR) Filaments and Monomers designed to propel research on TTR and its association with amyloid
Read moreStressMarq has developed unique alpha synuclein constructs to provide invaluable support to researchers engaged in disease model development and the
Read moreParkinson’s Disease is characterized by the aggregation of alpha-synuclein, a key pathological feature. In this informative video, the mechanism underlying
Read moreSonification: What, Why, How and Best Practices A StressMarq Biosciences .pdf White Paper Neurodegenerative Disease Research As populations age, the
Read more